Many cancer drugs recently approved in US do not improve overall survival, study findsBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5634 (Published 23 October 2015) Cite this as: BMJ 2015;351:h5634
- Michael McCarthy
In recent years most cancer drug approvals by the US Food and Drug Administration have been made on the basis of a surrogate endpoint, such as tumour response rate or progression-free survival. When such approvals are made the agency typically advises or requires that post-approval studies be conducted to clarify the drug’s effect on overall survival.
However, a new US study has found that, in most cases, cancer drugs that have recently secured FDA …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial